This is a working overview of Reversed-phase HPLC, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-10-25 and is reviewed periodically as new material appears.
The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.
In clinical research, tirzepatide has been studied in randomized controlled trials for glycemic control and body weight reduction. These trials typically measure changes in hemoglobin A1c and body weight over periods of several months. The drug is administered by subcutaneous injection, and its pharmacokinetic profile supports once-weekly dosing. Post-marketing surveillance continues to evaluate long-term outcomes and rare adverse events.
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
在生理层面，GIP 与 GLP-1 均为肠道内分泌细胞分泌的肠促胰素，进食后参与胰岛素分泌调节与胃排空抑制。Tirzepatide 通过同时激活这两条信号通路，使胰岛素分泌的葡萄糖依赖性增强，并延缓冲胃排空、降低食欲信号。与单一 GLP-1 激动相比，双靶点作用在血糖控制和体重变化上的效应幅度更大，但具体贡献比例仍在研究之中。
脂肪酸侧链的存在使该肽与血浆白蛋白结合能力增强，从而延长循环半衰期，支持每周一次给药的用药间隔。白蛋白结合同时改变组织分布特征，减慢肾脏清除速度。该设计思路在多种长效肽类药物中被反复采用，属于既定的药代动力学策略。
该化合物的名称与结构由国际非专利名称体系统一维持，不同文献中出现的同义写法主要在拼写顺序或盐形式描述上不同。研究者通常通过受体结合实验、细胞内环磷酸腺苷积累测定以及动物模型来确认其双激动活性。相当一部分分子层面的细节——例如两条受体通路之间的信号交叉作用——尚处于开放问题状态。
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Dual GIP/GLP-1 receptor agonist |
| Amino acid count | 39 | Contains non-natural residues |
| Modification | C20 fatty diacid | Attached via linker; promotes albumin binding |
| Half-life | Approximately 5 days | Supports once-weekly dosing |
| Primary route | Subcutaneous injection | Not for intravenous use |
Tirzepatide is a synthetic peptide of 39 amino acids engineered from the native glucose-dependent insulinotropic polypeptide sequence. Its structure incorporates several non-natural residues and a C-terminal segment derived from glucagon-like peptide-1, together with a C20 fatty diacid moiety attached through a linker. The lipophilic side chain promotes binding to serum albumin, which slows renal clearance after administration. The compound is classified as a dual incretin receptor agonist and is supplied as a lyophilized powder for reconstitution or as a preformulated solution, depending on the presentation.
The peptide activates two G protein-coupled receptors, GIPR and GLP-1R. Binding triggers adenylyl cyclase activity and raises intracellular cyclic AMP in pancreatic beta cells, which potentiates insulin release when glucose is elevated. Signaling in the central nervous system is associated with reduced appetite and lower energy intake, while effects on gastric emptying and glucagon secretion are also reported. Because activity at both receptors is retained, the pharmacological profile is often described as incretin-based rather than selective for a single receptor.
After subcutaneous injection, absorption is gradual, and peak plasma levels are generally reached within one to three days. Albumin binding extends the apparent half-life to roughly five days, which supports a weekly administration schedule. Metabolism proceeds mainly through proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid chain, rather than through cytochrome P450 pathways. Eliminated fragments are largely recycled through general protein turnover, and excretion of intact drug in urine is minimal. These properties distinguish the molecule from short-acting incretin mimetics.
Like most synthetic peptides of this size, the material is commonly supplied as a lyophilised powder that appears white to off-white. It dissolves in aqueous buffers and in mixtures of water with a small proportion of organic solvent, though the fatty acid portion reduces solubility in pure water relative to short peptides. Hygroscopic behaviour is reported for many peptide powders, so weighing is usually performed quickly and under controlled humidity. Working solutions are typically prepared fresh and kept cold.
Long-term storage of lyophilised peptide powder is generally at minus twenty degrees Celsius or colder, with desiccant and protection from light. Short-term storage at two to eight degrees Celsius is common during active use. In solution, stability depends strongly on pH, concentration, and the presence of preservatives, and hydrolysis or aggregation can develop over weeks. Published stability data specific to this molecule are limited, so recommended conditions for research material are usually extrapolated from general peptide handling practice rather than from a dedicated study.
Regulatory and quality discussions place the peptide within established guidance for synthetic peptides and biologics. Forced degradation studies, in which samples are exposed to heat, acid, base, peroxide, and light, identify likely degradation products and validate the selectivity of analytical methods. Reference standards allow comparison across laboratories and production batches. Purity specifications reported in the literature usually combine chromatographic purity with mass confirmation. Which impurity thresholds are meaningful for long-term behavior is still debated, and no single universal specification has been adopted across all jurisdictions.
Routine characterization of the peptide relies on reversed-phase high-performance liquid chromatography for purity assessment, usually with ultraviolet detection near 214 nanometers. Intact mass measurement by liquid chromatography coupled to mass spectrometry confirms molecular identity against a theoretical value. Sequence-level confirmation uses enzymatic digestion followed by tandem mass spectrometry, an approach known as peptide mapping. Amino acid analysis gives an independent check on composition. Circular dichroism spectra are used to estimate helical content in aqueous buffer.
Stability depends strongly on physical form. The dry powder is generally regarded as stable for extended periods when held at or below minus twenty degrees Celsius in a sealed, desiccated container. In solution, degradation pathways include deamidation of asparagine and glutamine residues, oxidation of methionine, and aggregation. Reaction rates for these pathways rise with temperature. Repeated freezing and thawing of solutions promotes aggregation, and light exposure can accelerate some oxidative changes. Buffer composition and pH influence which pathway dominates at a given temperature.
The colon can be involved, and can cause pseudo-obstruction or ischemic colitis. Rarer complications include pneumatosis cystoides intestinalis, or gas pockets in the bowel wall, wide-mouthed diverticula in the colon and esophagus, and liver fibrosis. Patients with severe gastrointestinal involvement can become profoundly malnourished. Scleroderma may also be associated with gastric antral vascular ectasia, also known as "watermelon stomach". This is a condition in which atypical blood vessels proliferate, usually in a radially symmetric pattern around the pylorus of the stomach. It can be a cause of upper gastrointestinal bleeding or iron-deficiency anemia in patients with scleroderma.
However, there is no real demand in chemistry, physics, or engineering for isolating 234U, and the small amounts that may be wanted for research can be separated chemically from plutonium-238 that have been aged enough to accumulate its alpha decay product, which is 234U. Enriched uranium contains more 234U than natural uranium as a byproduct of the uranium enrichment process aimed at obtaining uranium-235, which concentrates lighter isotopes even more strongly than it does 235U. IAEA research paper TECDOC-1529 concludes the 234U content of enriched fuel is directly proportional to the degree of 235U—enrichment with 2% 235U resulting in 150 g 234U/ton HM (heavy metals, special meaning, relating to nuclear fuels), and the most common 4.5% 235U enrichment resulting in 400 g 234U/ton HM. The increased percentage of 234U in enriched natural uranium is not harmful to the operation of current nuclear reactors. Uranium-234 has a neutron-capture cross section of about 100 barns for thermal neutrons, and about 700 barns for its resonance integral—the average of neutrons having a range of intermediate energies. In a nuclear reactor non-fissile isotopes 234U and 238U both capture a neutron, thereby breeding fissile isotopes 235U and 239Pu, respectively. 234U is converted to 235U more easily and therefore at a greater rate than 238U is to 239Pu (via neptunium-239) because 238U has a much smaller neutron-capture cross section of just 2.7 barns.
As more African-Americans are incarcerated, the more the heuristic is enforced in the eyes of the courts, which contributes to yet higher imprisonment rates among African-American children. High numbers of African American arrests and charges of possession show that although most drug users in the United States are white, blacks are the largest group being targeted as the root of the problem. Furthermore, a study by Andrew Golub, Bruce Johnson, and Eloise Dunlap affirms the racial divide in drug arrests, notably marijuana arrests, where blacks with no prior arrests (0.9%) or one prior arrest (4.3%) were nearly twice as likely to be sentenced to jail as their white counterparts (0.4% and 2.3%, respectively). Harboring such emotions can lead to a lack of will to contact the police in case of an emergency by members of African-American communities, ultimately leaving many people unprotected. Disproportionate arrests in African-American communities for drug-related offenses has not only spread fear but also perpetuated a deep distrust for government and what some call racist drug enforcement policy. Additionally, a black-white disparity can be seen in probation revocation since black probationers were revoked at higher rates than white and Hispanic probationers in studies as published under the Urban Institute.
Sources: en.wikipedia.org
Russian: музга, muzga "pool, puddle" Lithuanian: mazgoti and Latvian: mazgāt "to wash" Sanskrit: májjati "to drown" Latin: mergō "to dip, immerse" Prekmurje Slovene: müzga "marsh, swamp" In many Slavic countries, Moskov is a surname, most commonly in Russia, Bulgaria, Ukraine, and North Macedonia. In addition, similarly named places exist in Poland, such as Mozgawa. According to a Finno-Ugric hypothesis, the Merya and Muroma people—who were among the pre-Slavic tribes that inhabited the area—called the river Mustajoki ("Black River"), and the name of the river derives from this term. Other theories, having little or no scientific basis, are rejected by linguists. The Old Russian form of the city's name has been reconstructed as *Москы, *Mosky; hence the name was one of a few Slavic ū-stem nouns. As with other nouns of that declension, the name had been undergoing a morphological transformation during an early stage of the language's development; as a result, the first written references in the 12th century were to Московь, Moskovĭ (accusative case), Москви, Moskvi (locative case), and Москвe/Москвѣ, Moskve/Moskvě (genitive case). From the latter forms came the modern Russian form Москва, Moskva, which is a result of morphological generalization with numerous Slavic ā-stem nouns. The form Moskovĭ has left traces in other languages, including the following:
Secondary aromatic amines: These are less hindered than hindered phenols, which can make them more reactive. Hindered amine light stabilizers (HALS): Unlike other primary antioxidants, HALS scavenge free radicals generated during photo-oxidation, thus protecting the polymer material from UV radiation. Secondary antioxidants act to decompose peroxides (ROOH) into non-radical products, thus preventing further generation of free radicals, and contributing to the overall oxidative stability of the polymer. Often used in combination with phenolic antioxidants for synergistic effects. Phosphites: Example: tris(2,4-di-tert-butylphenyl)phosphite. Thiosynergists: Most of this class are "thio-ethers" (not to be confused with thioesters): an ester of 3,3-thiodipropionic acid. Other organic sulfide (R1-S-R2) compounds also have a similar effect. Radical scavengers: scavenge free radicals to halt the chain reaction. This can be any radical in the oxidation cycle (R•, ROO•, RO•, •OH), though in practice RO• and •OH are too reactive to "trap". Common types include lactones (esp. substituted benzofuranone) and acrylated bis-phenols.
=== Long-term === Finasteride may cause persistent adverse sexual, neurological, and physical effects in a subset of men. A 2019 systematic review surveyed the literature on the reversibility of finasteride's side effects. It identified three studies that demonstrated full reversibility of side effects and eleven that described patients with irreversible adverse events. A separate 2017 retrospective review of nearly 12,000 patients found 1.4% developed persistent (lasting at least 90 days after stopping Finasteride) ED, with this dropping to 0.8% for 16-42 year olds.
Sources: en.wikipedia.org
==== Canada ==== After completing medical school, internists in Canada require an additional four years of training. Internists desiring to subspecialize are required to complete two additional years of training that may begin after the third year of internist training. The Royal College of Physicians and Surgeons of Canada (RCPSC) is a national non-profit agency that oversees and accredits medical education in Canada. A full medical license in Internal Medicine in Canada requires a medical degree, a license from the Medical Council of Canada, completion of the required post-graduate education, and certification from the RCPSC. Any additional requirements from separate medical regulatory authorities in each province or territory is also required. Internists may practice in Canada as generalists in Internal Medicine or serve in one of seventeen subspecialty areas. Internists may work in many settings including outpatient clinics, inpatient wards, critical care units, and emergency departments. The currently recognized subspecialties include the following:
=== Enzymatic method for RNA oligonucleotide synthesis === One approach under investigation for overcoming length limitations in oligonucleotide synthesis involves the use of engineered enzymes to construct RNA sequences, rather than relying solely on traditional chemical methods. A key enzyme studied in this context is CID1 poly(U) polymerase (PUP), which naturally catalyzes the addition of nucleotides to the 3′ end of an RNA strand. In its native form, PUP functions as a template-independent polymerase, typically adding repeated sequence nucleotide tails to RNA molecules. To enable controlled sequence synthesis, enzymatic RNA synthesis has been adapted into a cyclic two-step process consisting of nucleotide extension and deblocking. During the extension step, a single nucleotide is enzymatically added, while the deblocking step removes a protecting group to allow subsequent incorporation. One investigated method involves the use of nucleoside triphosphates modified with a 3′-O-allyl blocking group. These modified nucleotides are synthesized and purified using techniques such as ion-exchange chromatography and preparative high-performance liquid chromatography (HPLC). Upon incorporation by PUP, the 3′-O-allyl group prevents further extension, thereby enabling single-nucleotide addition per cycle. Chemical removal of the blocking group then permits the next round of extension. Studies have shown that wild-type PUP exhibits limited efficiency when incorporating modified nucleotides.
Bats are placental mammals. After rodents, they are the largest order, making up about 20% of known mammal species. In 1758, Carl Linnaeus classified the seven bat species he knew of in the genus Vespertilio in the order Primates. Around twenty years later, the German naturalist Johann Friedrich Blumenbach gave them their own order, Chiroptera. Since then, the number of described species has risen to over 1,500, traditionally classified as two suborders: Megachiroptera (megabats) and Microchiroptera (microbats/echolocating bats). Not all megabats are larger than microbats. Several characteristics distinguish the two groups. Microbats use echolocation for navigation and finding prey, but megabats, apart from those in the genus Rousettus, do not. Accordingly, megabats have well-developed eyesight. Megabats have a claw on the second finger of the forelimb, external ears close to form a ring, and lack a tail. They only feed on plant material like fruit and nectar.
Ibogaine's hallucinogenic effects not being mediated by serotonin 5-HT2A receptor activation has been said to be in accordance with its hallucinogenic effects in humans being qualitatively distinct from and unlike those of serotonergic psychedelics but instead similar to those of harmala alkaloids. It is also in accordance with the fact that unlike serotonergic psychedelics like LSD, neither ibogaine nor harmala alkaloids cause pupil dilation or increase blood pressure in humans. Conversely, unlike serotonergic psychedelics, ibogaine and harmaline are said to cause balance disturbances and vomiting to a greater extent than any other psychoactive drug besides alcohol. Ibogaine shows appreciable affinity for the NMDA receptor. However, the NMDA receptor antagonists phencyclidine (PCP) and dizocilpine (MK-801) fail to substitute for ibogaine and ibogaine fails to substitute for these NMDA receptor antagonists in rodents and/or monkeys. Hence, NMDA receptor antagonism does not appear to be involved in the subjective effects of ibogaine. Neither μ-opioid receptor agonists nor κ-opioid receptor agonists like U-50,488 substitute for ibogaine. In addition, the opioid antagonist naloxone did not substitute for ibogaine. However, naltrexone partially substitutes for ibogaine. In addition, the mixed opioid agonists and antagonists pentazocine, diprenorphine, and nalorphine partially substituted for ibogaine and this could be antagonized by naloxone. The preceding findings suggest a role of opioid receptors but not the NMDA receptor in the effects of ibogaine.
Sources: en.wikipedia.org
It activates both GIP and GLP-1 receptors. This dual action differentiates it from selective GLP-1 agonists.
It is given as a subcutaneous injection. Its long half-life supports weekly dosing.
No, it is synthetic. It contains non-natural amino acids and a fatty acid modification.
它属于合成修饰肽，同时激动 GIP 与 GLP-1 两种肠促胰素受体。这类分子通常被称为双重肠促胰素受体激动剂，与选择性 GLP-1 激动剂在靶点范围上不同。